XML 77 R22.htm IDEA: XBRL DOCUMENT
v3.22.4

Fair Value Measurements (Tables) | 9 Months Ended | 11 Months Ended
--- | --- | ---
Sep. 30, 2022 | Dec. 31, 2021
Fair Value Measurements [Abstract] |  |
Schedule of financial assets and liabilities that are measured at fair value on a recurring basis |
Description |  | Quoted Prices in Active Markets (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Significant Other Unobservable Inputs (Level 3)
Assets: |  |  |  |  |  |  |  |  |
Investments held in Trust Account – money market fund |  | $ | 347,036,376 |  | $ | — |  | $ | —
Liabilities: |  |  |  |  |  |  |  |  |
Derivative warrant liabilities – Public |  | $ | 2,749,650 |  | $ | — |  | $ | —
Derivative warrant liabilities – Private Placement |  | $ | — |  | $ | — |  | $ | 4,419,950
Description |  | Quoted Prices in Active Markets (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Significant Other Unobservable Inputs (Level 3)
Assets: |  |  |  |  |  |  |  |  |
Investments held in Trust Account – money market fund |  | $ | 345,044,341 |  | $ | — |  | $ | —
Liabilities: |  |  |  |  |  |  |  |  |
Derivative warrant liabilities – Public |  | $ | 12,937,500 |  | $ | — |  | $ | —
Derivative warrant liabilities – Private Placement |  | $ | — |  | $ | — |  | $ | 17,140,250
Description |  | Quoted Prices in Active Markets (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Significant Other Unobservable Inputs (Level 3)
Assets: |  |  |  |  |  |  |  |  |
Investments held in Trust Account – money market fund |  | $ | 345,044,341 |  | $ | — |  | $ | —
Liabilities: |  |  |  |  |  |  |  |  |
Derivative warrant liabilities – Public |  | $ | 12,937,500 |  | $ | — |  | $ | —
Derivative warrant liabilities – Private Placement |  | $ | — |  | $ | — |  | $ | 17,140,250
Schedule of quantitative information regarding Level 3 fair value measurements inputs |
|  | September 30, 2022 |  | December 31, 2021
Exercise price |  | $ | 11.50 |  |  | $ | 11.50 |
Stock price |  | $ | 9.85 |  |  | $ | 10.00 |
Volatility |  |  | 42.35 | % |  |  | 21.82 | %
Term |  |  | 5.54 |  |  |  | 5.46 |
Risk-free rate |  |  | 4.00 | % |  |  | 1.30 | %
Dividend yield |  |  | 0.0 | % |  |  | 0.0 | %
|  | December 31, 2021 |  | At initial issuance
Exercise price |  | $ | 11.50 |  |  | $ | 11.50
Stock price |  | $ | 10.00 |  |  | $ | 9.70
Volatility |  |  | 21.82 | % |  |  | 16.82% – 17.02%
Term |  |  | 5.46 |  |  |  | 6.00
Risk-free rate |  |  | 1.30 | % |  |  | 1.05% – 1.09%
Dividend yield |  |  | 0.0 | % |  |  | 0.0%
Schedule of change in the fair value of the derivative warrant liabilities |
Derivative warrant liabilities at December 31, 2021 |  | $ | 17,140,250 |
Change in fair value of derivative warrant liabilities |  |  | (10,305,950 | )
Derivative warrant liabilities at March 31, 2022 |  |  | 6,834,300 |
Change in fair value of derivative warrant liabilities |  |  | (3,481,460 | )
Derivative warrant liabilities at June 30, 2022 |  |  | 3,352,840 |
Change in fair value of derivative warrant liabilities |  |  | 1,067,110 |
Derivative warrant liabilities at September 30, 2022 |  | $ | 4,419,950 |
Derivative warrant liabilities at February 2, 2021 |  | $ | — |
Issuance of Public and Private Placement Warrants |  |  | 21,160,000 |
Loss upon issuance of Private Placement Warrants |  |  | 2,175,000 |
Change in fair value of derivative warrant liabilities |  |  | 3,505,250 |
Derivative warrant liabilities at June 30, 2021 (Unaudited) |  |  | 26,840,250 |
Transfer of Public Warrants to Level 1 |  |  | (11,471,250 | )
Change in fair value of derivative warrant liabilities |  |  | 2,985,510 |
Derivative warrant liabilities at September 30, 2021 (Unaudited) |  | $ | 18,354,510 |
Derivative warrant liabilities at February 2, 2021 |  | $ | — |
Issuance of Public and Private Placement Warrants |  |  | 21,160,000 |
Loss upon issuance of Private Placement Warrants |  |  | 2,175,000 |
Transfer of Public Warrants to Level 1 |  |  | (11,471,250 | )
Change in fair value of derivative warrant liabilities |  |  | 5,276,500 |
Derivative warrant liabilities at December 31, 2021 |  | $ | 17,140,250 |

X
- References No definition available. + Details
Name: | roni_FairValueMeasurementsTablesLineItems
Namespace Prefix: | roni_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13572-108611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 23 -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13587-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611 + Details
Name: | us-gaap_FairValueConcentrationOfRiskTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of derivative liabilities at fair value. + References No definition available. + Details
Name: | us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration